NewsBenzingaEntegris prevé un BPA ajustado del cuarto trimestre de entre $1.32 y $1.40, frente a los $1.11 estimados; prevé ventas de entre $1.025B y $1.055B, frente a los $959.240M estimados Entegris prevé un BPA ajustado del cuarto trimestre de entre $1.32 y $1.40, frente a los $1.11 estimados; prevé ventas de entre $1.025B y $1.055B, frente a los $959.240M estimados Benzinga 2026.10.29 11:09 (GMT+0) Open on Benzinga Other news Keybanc Reiterates Sector Weight on NVIDIAto Sector Weight Top 3 Tech Stocks That May Fall Off A Cliff This Month Truist Securities Maintains Hold on BILL Holdings, Raises Price Target to $66 Nvidia’s China Exit Could Trigger a Bull-Bear Showdown: 6 Leveraged ETFs to Watch Wednesday OTraces Selects Labcorp To Perform Reference Laboratory Testing For Florida Department Of Health–Funded Clinical Trial Evaluating OTraces Blood-Based Prostate Cancer Diagnostic Platform Quanterix Affirms FY2026 Sales Guidance of $142.000M-$146.000M vs $143.357M Est
OTraces Selects Labcorp To Perform Reference Laboratory Testing For Florida Department Of Health–Funded Clinical Trial Evaluating OTraces Blood-Based Prostate Cancer Diagnostic Platform